首页> 美国卫生研究院文献>Nutrients >Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile Infection in Nephrology and Transplantation Ward—Results of One Year Extended Study
【2h】

Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile Infection in Nephrology and Transplantation Ward—Results of One Year Extended Study

机译:植物乳杆菌299v降低了肾脏病和移植病房中难辨梭状芽胞杆菌感染的发生率-延长一年的研究结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background:Lactobacillus plantarum 299v (LP299v) is a probiotic strain which influences on the intestinal bacterial flora. This is why, it has been introduced into clinical practice for the prevention and treatment of diarrheal disorders and alleviation of their symptoms in patients during antibiotic therapy. However, the use of probiotics in the prophylaxis of Clostridium difficile infections (CDI) in these patients is problematic. The aim of this clinical, retrospective, single-centre study was to analyse the incidence of CDI among patients hospitalized in the nephrology and transplantation ward in the period before, during and after stopping of LP299v prophylaxis. >Methods: Among 5341 patients hospitalized in the nephrology and transplantation ward over a three year period, 34 patients with CDI were diagnosed and included in this analysis. From December 2013 to December 2014 all patients under antibiotic and immunosuppressive therapies received LP299v as a prophylaxis of CDI. The observation period consisted of three twelve-months periods: before, during LP299v use and after stopping of such method of CDI prevention. >Results: A significant (p = 0.0003) reduction of CDI incidence during LP299v use (0.11%) was observed compared to two other periods, that is, before and after LP299v use (1.03% and 0.77%, respectively). >Conclusions: Routine use of LP299v as a CDI prophylaxis may prevent CDI during antibiotics therapy in patients treated with immunosuppressive agents in nephrology and transplantation ward.
机译:>背景:植物乳杆菌299v(LP299v)是一种益生菌菌株,会影响肠道细菌菌群。这就是为什么将其引入到临床实践中以预防和治疗抗生素治疗期间腹泻性疾病和减轻患者症状的原因。然而,在这些患者中使用益生菌预防艰难梭菌感染(CDI)是有问题的。这项临床回顾性单中心研究的目的是分析在停止LP299v预防的前后,期间在肾病和移植病房住院的患者中CDI的发生率。 >方法:在为期三年的肾病和移植病房住院的5341例患者中,诊断出34例CDI患者,并将其纳入分析。从2013年12月至2014年12月,所有接受抗生素和免疫抑制疗法的患者均接受LP299v预防CDI。观察期包括三个十二个月的时期:在使用LP299v之前,期间以及停止这种CDI预防方法之后。 >结果:与其他两个时期(即LP299v使用前后)(1.03%和0.77%)相比,使用LP299v期间CDI发生率显着降低(p = 0.0003)(0.11%),分别)。 >结论:在肾脏病房和移植病房中,常规使用LP299v作为CDI预防剂可能会在抗生素治疗期间预防CDI的患者接受免疫抑制剂治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号